KRAS and neoplasm: Patients with crizoltinib-resistant circulating tumor cells (CTC) had repeated mutations in the RTK-KRAS (EGFR, KRAS, BRAF genes), TP53, and other genes in the ALK-independent pathway, according to single CTC sequencing [108].